Amylyx discontinues production of RELYVRIO by October 31, 2024

Amylyx, developers of RELYVRIO will stop shipping the drug starting Thursday, October 31, 2024, and are voluntarily discontinuing RELYVRIO from the U.S. market based on the topline results from the Phase 3 PHOENIX trial. For those still taking RELYVRIO , a one-time shipment of enough RELYVRIO packets can be ordered to last until Friday, January 31, 2025. 

The ALS Network is your connection to news and information impacting the ALS community.